Janet I. Swearson
Profile
Janet I.
Swearson served as Chief Financial Officer at Threshold Pharmaceuticals, Inc. and Receptor BioLogix, Inc. She holds an MBA from Santa Clara University and an undergraduate degree from the University of Minnesota.
Former positions of Janet I. Swearson
| Companies | Position | End |
|---|---|---|
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Director of Finance/CFO | 30/08/2006 |
Receptor BioLogix, Inc.
 Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Director of Finance/CFO | - |
Training of Janet I. Swearson
| Santa Clara University | Masters Business Admin |
| University of Minnesota | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Receptor BioLogix, Inc.
Receptor BioLogix, Inc. BiotechnologyHealth Technology Receptor BioLogix, Inc. provides receptor based biological therapeutics. It develops an intron fusion protein platform for the discovery of novel alternative forms splice variants of human proteins with therapeutic potential. The company was founded by H. Michael Shepard, John P. Adelman and Gail M. Clinton on May 27, 2003 and is headquartered in Mountain View, CA. | Health Technology |
- Stock Market
- Insiders
- Janet I. Swearson